Quick Answer

Zepbound and Mounjaro contain the exact same medication — tirzepatide — made by the same company (Eli Lilly). The only differences are FDA approval and pricing. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management. If you don’t have diabetes, Zepbound is the appropriate prescription. If you have type 2 diabetes, Mounjaro may offer better insurance coverage.

Key Takeaways

• Same drug: Both contain tirzepatide, a dual GIP/GLP-1 receptor agonist
• Same manufacturer: Eli Lilly makes both medications
• Same doses: Both available in 2.5mg through 15mg weekly injections
• Different FDA approvals: Mounjaro for diabetes, Zepbound for weight loss
• Different pricing: Mounjaro ~$1,023-1,176/month, Zepbound ~$1,059-1,112/month
• Different coverage: Mounjaro often covered for diabetics; Zepbound rarely covered for weight loss

Understanding Tirzepatide

Before comparing Zepbound and Mounjaro, it helps to understand what tirzepatide actually does.

Tirzepatide is a dual-action medication that works on two hormone receptors:

GLP-1 (Glucagon-Like Peptide-1): This is the same receptor targeted by semaglutide (Ozempic, Wegovy). Activating GLP-1 receptors slows stomach emptying, increases insulin release, and reduces appetite.

GIP (Glucose-Dependent Insulinotropic Polypeptide): This is unique to tirzepatide. GIP activation provides additional metabolic benefits, including enhanced insulin sensitivity and potentially greater effects on fat tissue.

This dual mechanism is why tirzepatide has shown greater weight loss results than single-action GLP-1 medications in clinical trials.

Zepbound vs Mounjaro: Complete Comparison

Why Two Names for the Same Drug?

Pharmaceutical companies often sell the same medication under different names for different FDA-approved uses. This happens because:

Separate clinical trials: Eli Lilly conducted different trial programs — SURPASS for diabetes and SURMOUNT for weight loss — to gain separate FDA approvals.

Different prescribing requirements: Each FDA indication comes with specific labeling, dosing guidance, and prescribing requirements.

Insurance billing: Having separate drugs allows for distinct billing codes, which affects insurance coverage.

Marketing: Different branding allows targeted marketing to different patient populations and healthcare providers.

FDA Approval Differences

Mounjaro: Type 2 Diabetes

Mounjaro was FDA-approved in May 2022 for adults with type 2 diabetes as an adjunct to diet and exercise. The approval was based on the SURPASS clinical trial program, which included over 5,000 patients.

Key trial results (SURPASS-2):

• Average A1C reduction: 2.0-2.3% (vs 1.9% for semaglutide)
• Average weight loss: 8-13% of body weight
• More patients reached A1C targets than with other diabetes medications

Who qualifies for Mounjaro:

• Adults with type 2 diabetes
• Not recommended for type 1 diabetes
• Not recommended for patients with history of medullary thyroid carcinoma

Zepbound: Weight Management

Zepbound was FDA-approved in November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition.

Key trial results (SURMOUNT-1):

• Average weight loss: 15-21% of body weight
• 91% of patients lost at least 5% of their weight
• 57% of patients lost at least 20% of their weight

Who qualifies for Zepbound:

• Adults with BMI ≥30 (obesity)
• Adults with BMI ≥27 plus at least one weight-related condition (hypertension, type 2 diabetes, high cholesterol, sleep apnea)
• Used alongside reduced-calorie diet and increased physical activity

Dosing: Identical Schedules

Both Zepbound and Mounjaro follow the same titration schedule:

The starting dose of 2.5mg is intentionally subtherapeutic — it’s designed to let your body adjust to the medication before reaching effective doses. Most side effects occur early in treatment and during dose increases.

Important: Dose increases should happen every 4 weeks minimum. Your doctor may keep you at a lower dose longer if:

• You’re experiencing significant side effects
• You’re achieving adequate results at a lower dose
• You have concerns about tolerability

Many patients find their optimal dose before reaching 15mg. There’s no requirement to reach the maximum dose.

Cost Comparison

List Prices (Without Insurance)

Prices are similar because they’re manufactured by the same company with the same production costs.

With Manufacturer Savings

Both medications offer savings programs:

Mounjaro Savings Card:

• Eligible patients pay as little as $25/month
• Requires commercial insurance
• Not valid for Medicare, Medicaid, or uninsured patients
• Maximum savings of $150 per fill (up to 12 fills)

Zepbound Savings Card:

• With insurance: As low as $25/month
• Without insurance: $550/month (approximately half off retail)
• Not valid for Medicare, Medicaid, or government programs
• Maximum savings apply

Insurance Coverage Realities

Mounjaro coverage (for diabetes):

• Most commercial plans cover with prior authorization
• Medicare Part D: Often covered for diabetes
• Medicaid: Varies by state, often covered
• Typical copay with coverage: $25-150/month

Zepbound coverage (for weight loss):

• Most commercial plans exclude weight loss drugs
• Medicare: Federal law prohibits coverage of weight loss medications
• Medicaid: Almost never covered
• Only ~20-25% of commercial plans cover weight loss drugs

This coverage disparity is the main practical difference between Zepbound and Mounjaro.

Side Effects: Identical Profiles

Since both medications contain tirzepatide, they produce identical side effects:

Common Side Effects (>5% of patients)

Gastrointestinal:

• Nausea (most common, especially early in treatment)
• Diarrhea
• Constipation
• Vomiting
• Abdominal pain
• Decreased appetite

Injection site:

• Redness
• Swelling
• Itching

Serious Side Effects (Rare)

Pancreatitis: Inflammation of the pancreas. Stop medication and seek medical attention if you experience severe abdominal pain that radiates to your back.

Gallbladder problems: Rapid weight loss can increase gallstone risk. Symptoms include right upper abdominal pain, especially after eating fatty foods.

Kidney issues: Usually related to dehydration from GI side effects. Stay well-hydrated.

Thyroid tumors: Tirzepatide carries a black box warning about thyroid C-cell tumors observed in rodent studies. Not recommended for patients with personal or family history of medullary thyroid carcinoma or MEN 2.

Hypoglycemia: Primarily a concern when combined with insulin or sulfonylureas. Less common when used alone.

Allergic reactions: Rare but possible. Seek immediate care for rash, swelling, or difficulty breathing.

Managing Side Effects

Side effects are most common during the first few weeks and when increasing doses. Strategies to minimize discomfort:

Eat smaller meals: Large meals are more likely to cause nausea when stomach emptying is slowed.

Avoid fatty foods: High-fat meals are harder to digest and more likely to cause GI symptoms.

Stay hydrated: Drink plenty of water, especially if experiencing diarrhea or vomiting.

Eat slowly: Give your body time to register fullness.

Consider timing: Some patients find taking injections at bedtime helps them sleep through initial nausea.

Talk to your doctor: If side effects are severe, a slower titration schedule may help.

Which Should You Choose?

Choose Mounjaro If:

You have type 2 diabetes. Mounjaro is specifically approved for diabetes management and will help both blood sugar and weight.

Your insurance covers diabetes medications. Most plans cover Mounjaro for diabetes with prior authorization.

You want to use manufacturer savings. The Mounjaro savings card can bring costs to $25/month with commercial insurance.

Your doctor is comfortable prescribing it. Some providers are more familiar with Mounjaro due to its longer time on the market.

Choose Zepbound If:

You don’t have diabetes. Zepbound is the appropriate on-label choice for weight management without diabetes.

Your insurance covers weight loss drugs. If your plan covers Zepbound, using it on-label is preferable.

You’re paying cash. The Zepbound savings card offers $550/month pricing without insurance — slightly cheaper than Mounjaro’s full retail.

You want to avoid off-label use. Some patients prefer using medications for their FDA-approved purpose.

The Off-Label Reality

Many patients use Mounjaro off-label for weight loss because:

• Insurance coverage is better for diabetes indications
• Mounjaro has been available longer
• Some providers prefer prescribing established medications

This practice is legal and medically common. Physicians can prescribe FDA-approved drugs for off-label uses based on clinical judgment.

However, if caught, insurance companies can deny coverage for off-label prescriptions, and patients may face repayment demands.

Effectiveness: Same Results

Since both medications contain identical tirzepatide:

Weight loss: Both produce 15-21% average weight loss at maximum doses based on clinical trials.

Blood sugar control: Both reduce A1C by 2.0-2.3% in diabetic patients.

Appetite suppression: Both work through the same mechanisms to reduce hunger and food cravings.

Metabolic benefits: Both improve insulin sensitivity, blood pressure, and cholesterol profiles.

There is no scenario where Zepbound would work but Mounjaro wouldn’t, or vice versa. They are pharmacologically identical.

Switching Between Zepbound and Mounjaro

Can you switch between them? Yes, easily.

Same dose transition: If you’re on Mounjaro 7.5mg, you can switch directly to Zepbound 7.5mg (or vice versa).

No washout period: Since they’re the same medication, no gap is needed.

Reasons to switch:

• Insurance changes (plan starts or stops covering one)
• Availability issues (one may be in shortage while the other is available)
• Cost changes (savings programs evolve)

How to switch:

• Contact your doctor for a new prescription
• Inform your pharmacy
• Continue with the same injection schedule

Compounded Tirzepatide: A Third Option

For patients who can’t afford brand-name Mounjaro or Zepbound, compounded tirzepatide from providers like Direct Meds from telehealth providers offers an alternative.

Compounded Tirzepatide Pricing

Trade-offs

Advantages:

• 60-70% cost savings
• No insurance needed
• Same active ingredient

Disadvantages:

• NOT FDA-approved
• Quality varies by pharmacy
• Less regulatory oversight
• No insurance coverage

Compounded tirzepatide contains the same active ingredient as Mounjaro and Zepbound but is produced by compounding pharmacies rather than Eli Lilly.

Clinical Trial Results

SURPASS Trials (Mounjaro/Diabetes)

The SURPASS program included multiple trials comparing tirzepatide to other diabetes treatments:

SURPASS-2 (vs semaglutide):

• Tirzepatide produced greater A1C reductions: -2.0% to -2.3% vs -1.9%
• Tirzepatide produced greater weight loss: -8% to -13% vs -7%
• More patients reached A1C under 7% with tirzepatide

SURPASS-4 (vs insulin glargine):

• Tirzepatide showed superior A1C control
• Tirzepatide patients lost weight while insulin patients gained weight

SURMOUNT Trials (Zepbound/Weight Loss)

The SURMOUNT program studied tirzepatide specifically for weight management:

SURMOUNT-1 (vs placebo):

• 5mg dose: 15% average weight loss
• 10mg dose: 19.5% average weight loss
• 15mg dose: 20.9% average weight loss
• 57% of patients on 15mg lost at least 20% of body weight

SURMOUNT-2 (diabetic patients):

• 10mg dose: 12.8% weight loss
• 15mg dose: 14.7% weight loss
• Also showed significant A1C improvements

Frequently Asked Questions

Is Zepbound stronger than Mounjaro?

No. They contain identical tirzepatide at identical doses. Zepbound is not a “stronger” version — it’s the same drug with different FDA labeling.

Can I use Mounjaro for weight loss if I don’t have diabetes?

Technically yes, but it would be off-label. Some doctors prescribe Mounjaro off-label for weight loss, especially if insurance coverage is better. However, Zepbound is the FDA-approved option for weight loss.

Will my insurance cover either one?

Coverage depends on your specific plan. Generally:

• For diabetes: Mounjaro is more likely to be covered
• For weight loss: Neither may be covered (most plans exclude weight loss drugs)

Check with your insurance directly or ask your pharmacy to run a benefits check.

Are there generic versions of Zepbound or Mounjaro?

No. Eli Lilly holds patents on tirzepatide through 2036. No generic versions will be available until then. Compounded versions exist but are not FDA-approved generics.

Which has fewer side effects?

Neither. Same drug means same side effect profile. If you couldn’t tolerate one, you won’t tolerate the other.

Can I take Zepbound and Mounjaro together?

No. Never take both simultaneously — that would be a double dose of the same medication and could be dangerous.

What if one is out of stock?

If your medication faces a shortage, you can ask your doctor to prescribe the other version. They’re interchangeable.

The Bottom Line

Zepbound and Mounjaro are the same medication — tirzepatide — with different FDA approvals and branding. The choice between them comes down to:

Your diagnosis: Diabetes favors Mounjaro; pure weight loss favors Zepbound.

Insurance coverage: Check which your plan covers, if any.

Your doctor’s preference: Some providers prefer one based on familiarity.

Cost considerations: Both have savings programs; compare what you’d actually pay.

From an effectiveness standpoint, there’s no difference. You’re choosing packaging and billing codes, not different medicines.

If cost is the primary barrier, compounded tirzepatide from providers like Direct Meds offers a significantly cheaper alternative, though without FDA approval.

Talk to your doctor about which option makes the most sense for your specific situation.